CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

Pilatus doses first patient in Phase I PLT012 trial for HCC

Trial StartPLT012Positive
AI Analysis

Summary

Pilatus Biosciences has dosed the first patient in a Phase I clinical trial of PLT012, an investigational therapy for hepatocellular carcinoma, in Hong Kong.

Clinical Trial Data

Phase

Phase 1

Patients

1

Importance:3/10
Sentiment:
0.30
clinical trialPhase 1HCCpatient dosing
Related Companies

Read the original article

Published by Clinical Trials Arena on October 15, 2026 7:56 AM

Read Original